IMVT - Company ID 0001764013
The table below shows Immunovant, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$117.41M | -$76.20M | -$47.37M | -$65.82M | -$21.21M | -$13.80M |
| Capital expenditure | $0.00 | $182.00K | $45.00K | $42.00K | $18.00K | $47.00K |
| Investing cash flow | $0.00 | -$182.00K | -$45.00K | -$42.00K | -$18.00K | -$47.00K |
| Dividends paid | - | - | - |
Immunovant, Inc. reported operating cash flow of -$407.31M for fiscal year 2026. That is down 8.4% from -$375.87M in fiscal 2025. Over the 8 fiscal years shown, operating cash flow declined from -$28.55M (FY 2019) to -$407.31M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.92M | $686.00K | $890.00K | $21.00K | $91.00K | $193.55M |